Skip to main content
Top
Published in: Infection 1/2013

01-02-2013 | Clinical and Epidemiological Study

Hepatitis E virus and hepatitis A virus exposures in an apparently healthy high-risk population in Italy

Authors: M. Rapicetta, R. Monarca, L. A. Kondili, P. Chionne, E. Madonna, G. Madeddu, A. Soddu, A. Candido, S. Carbonara, M. S. Mura, G. Starnini, S. Babudieri

Published in: Infection | Issue 1/2013

Login to get access

Abstract

Purpose

The prevalence of anti-hepatitis E virus (HEV) and anti-hepatitis A virus (HAV), as well as the possible links with socio-demographic and other viral risks factors, were evaluated in an inmates population.

Methods

The study population consisted of 973 consecutively recruited inmates of eight Italian prisons.

Results

The anti-HEV prevalence was 11.6 % (113/973). It increased significantly by age (χ2 for linear trend: p = 0.001) and was significantly higher among non-Italian compared to Italian inmates (15.3 vs. 10.7 %, respectively). Age >40 years [odds ratio (OR) 2.1; 95 % confidence interval (CI) 1.4–3.1], non-Italian citizenship (OR 1.8; 95 % CI 1.1–2.9) and anti-HIV seropositivity (OR 2.2; 95 % CI 1.2–4.2) were the only factors independently associated to anti-HEV positivity by logistic regression analysis. The overall anti-HAV prevalence was 86.4 %, and was significantly higher in non-Italian compared to Italian prisoners (92.6 vs. 84.9 %, respectively; p = 0.02). Age older than 40 years (OR 3.6; 95 % CI 2.2–5.9), <5 years formal education (OR 2.1; 95 % CI 1.3–3.2) and non-Italian nationality (OR 2.7; 95 % CI 1.5–4.8) were factors independently associated to anti-HAV positivity by the logistic regression analysis.

Conclusions

Compared to the general population, significantly higher anti-HEV and anti-HAV prevalences were observed in an inmates population in Italy. Old age and non-Italian nationality were factors independently related to both HEV and HAV exposures. This data suggest the important role of low socio-economic factors in the transmission of both infections in high-risk populations. The possible epidemiological and/or pathogenetic links between HEV and HIV exposures need to be studied further.
Literature
1.
go back to reference Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol. 2008;48:494–503.PubMedCrossRef Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol. 2008;48:494–503.PubMedCrossRef
3.
go back to reference Preiss JC, Plentz A, Engelmann E, Schneider T, Jilg W, Zeitz M, et al. Autochthonous hepatitis E virus infection in Germany with sequence similarities to other European isolates. Infection. 2006;34:173–5.PubMedCrossRef Preiss JC, Plentz A, Engelmann E, Schneider T, Jilg W, Zeitz M, et al. Autochthonous hepatitis E virus infection in Germany with sequence similarities to other European isolates. Infection. 2006;34:173–5.PubMedCrossRef
4.
go back to reference Pfefferle S, Frickmann H, Gabriel M, Schmitz N, Günther S, Schmidt-Chanasit J. Fatal course of an autochthonous hepatitis E virus infection in a patient with leukemia in Germany. Infection. 2011;40:451–4. doi:10.1007/s15010-011-0220-7 PubMedCrossRef Pfefferle S, Frickmann H, Gabriel M, Schmitz N, Günther S, Schmidt-Chanasit J. Fatal course of an autochthonous hepatitis E virus infection in a patient with leukemia in Germany. Infection. 2011;40:451–4. doi:10.​1007/​s15010-011-0220-7 PubMedCrossRef
5.
go back to reference Brost S, Wenzel JJ, Ganten TM, Filser M, Flechtenmacher C, Boehm S, et al. Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany. J Clin Virol. 2010;47:89–92.PubMedCrossRef Brost S, Wenzel JJ, Ganten TM, Filser M, Flechtenmacher C, Boehm S, et al. Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany. J Clin Virol. 2010;47:89–92.PubMedCrossRef
6.
go back to reference Friestad C. Socio-economic status and health in a marginalized group: the role of subjective social status among prison inmates. Eur J Public Health. 2010;20:653–8.PubMedCrossRef Friestad C. Socio-economic status and health in a marginalized group: the role of subjective social status among prison inmates. Eur J Public Health. 2010;20:653–8.PubMedCrossRef
7.
go back to reference Reimer J, Lorenzen J, Baetz B, Fischer B, Rehm J, Haasen C, et al. Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol. 2007;22:80–5.PubMedCrossRef Reimer J, Lorenzen J, Baetz B, Fischer B, Rehm J, Haasen C, et al. Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol. 2007;22:80–5.PubMedCrossRef
8.
go back to reference Badiaga S, Raoult D, Brouqui P. Preventing and controlling emerging and reemerging transmissible diseases in the homeless. Emerg Infect Dis. 2008;14:1353–9.PubMed Badiaga S, Raoult D, Brouqui P. Preventing and controlling emerging and reemerging transmissible diseases in the homeless. Emerg Infect Dis. 2008;14:1353–9.PubMed
9.
go back to reference Babudieri S, Longo B, Sarmati L, Starnini G, Dori L, Suligoi B, et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005;76:311–7.PubMedCrossRef Babudieri S, Longo B, Sarmati L, Starnini G, Dori L, Suligoi B, et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005;76:311–7.PubMedCrossRef
10.
go back to reference Watkins RE, Mak DB, Connelly C. Testing for sexually transmitted infections and blood borne viruses on admission to Western Australian prisons. BMC Public Health. 2009;9:385.PubMedCrossRef Watkins RE, Mak DB, Connelly C. Testing for sexually transmitted infections and blood borne viruses on admission to Western Australian prisons. BMC Public Health. 2009;9:385.PubMedCrossRef
11.
go back to reference Lin CF, Twu SJ, Chen PH, Cheng JS, Wang JD. Prevalence and determinants of hepatitis B antigenemia in 15,007 inmates in Taiwan. J Epidemiol. 2010;20:231–6.PubMedCrossRef Lin CF, Twu SJ, Chen PH, Cheng JS, Wang JD. Prevalence and determinants of hepatitis B antigenemia in 15,007 inmates in Taiwan. J Epidemiol. 2010;20:231–6.PubMedCrossRef
12.
go back to reference Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A. Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Braz J Infect Dis. 2009;13:356–8.PubMedCrossRef Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A. Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Braz J Infect Dis. 2009;13:356–8.PubMedCrossRef
13.
go back to reference Kazi AM, Shah SA, Jenkins CA, Shepherd BE, Vermund SH. Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan. Int J Infect Dis. 2010;14:e60–6.PubMedCrossRef Kazi AM, Shah SA, Jenkins CA, Shepherd BE, Vermund SH. Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan. Int J Infect Dis. 2010;14:e60–6.PubMedCrossRef
14.
go back to reference Whiteman D, McCall B, Falconer A. Prevalence and determinants of hepatitis A virus exposure among prison entrants in Queensland, Australia: implications for public health control. J Viral Hepat. 1998;5:277–83.PubMedCrossRef Whiteman D, McCall B, Falconer A. Prevalence and determinants of hepatitis A virus exposure among prison entrants in Queensland, Australia: implications for public health control. J Viral Hepat. 1998;5:277–83.PubMedCrossRef
15.
go back to reference Zhou YH, Purcell RH, Emerson SU. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. Vaccine. 2004;22:2578–85.PubMedCrossRef Zhou YH, Purcell RH, Emerson SU. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. Vaccine. 2004;22:2578–85.PubMedCrossRef
16.
go back to reference Obriadina A, Meng JH, Ulanova T, Trinta K, Burkov A, Fields HA, et al. A new enzyme immunoassay for the detection of antibody to hepatitis E virus. J Gastroenterol Hepatol. 2002;17:S360–4.PubMedCrossRef Obriadina A, Meng JH, Ulanova T, Trinta K, Burkov A, Fields HA, et al. A new enzyme immunoassay for the detection of antibody to hepatitis E virus. J Gastroenterol Hepatol. 2002;17:S360–4.PubMedCrossRef
17.
go back to reference Ferguson M, Walker D, Mast E, Fields H. Report of a collaborative study to assess the suitability of a reference reagent for antibodies to hepatitis E virus. Biologicals. 2002;30:43–8.PubMedCrossRef Ferguson M, Walker D, Mast E, Fields H. Report of a collaborative study to assess the suitability of a reference reagent for antibodies to hepatitis E virus. Biologicals. 2002;30:43–8.PubMedCrossRef
18.
go back to reference Matsubayashi K, Kang JH, Sakata H, Takahashi K, Shindo M, Kato M, et al. A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion. 2008;48:1368–75.PubMedCrossRef Matsubayashi K, Kang JH, Sakata H, Takahashi K, Shindo M, Kato M, et al. A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion. 2008;48:1368–75.PubMedCrossRef
19.
go back to reference Borgen K, Herremans T, Duizer E, Vennema H, Rutjes S, Bosman A, et al. Non-travel related hepatitis E virus genotype 3 infections in the Netherlands; a case series 2004–2006. BMC Infect Dis. 2008;8:61. doi:10.1186/1471-2334-8-61.PubMedCrossRef Borgen K, Herremans T, Duizer E, Vennema H, Rutjes S, Bosman A, et al. Non-travel related hepatitis E virus genotype 3 infections in the Netherlands; a case series 2004–2006. BMC Infect Dis. 2008;8:61. doi:10.​1186/​1471-2334-8-61.PubMedCrossRef
20.
go back to reference Lewis HC, Wichmann O, Duizer E. Transmission routes and risk factors for autochthonous hepatitis E virus infection in Europe: a systematic review. Epidemiol Infect. 2010;138:145–66.PubMedCrossRef Lewis HC, Wichmann O, Duizer E. Transmission routes and risk factors for autochthonous hepatitis E virus infection in Europe: a systematic review. Epidemiol Infect. 2010;138:145–66.PubMedCrossRef
21.
go back to reference FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis A and E: update on prevention and epidemiology. Viral Hepatitis Prevention Board (VHPB): Conference Report. Vaccine. 2010;28:583–8.PubMedCrossRef FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis A and E: update on prevention and epidemiology. Viral Hepatitis Prevention Board (VHPB): Conference Report. Vaccine. 2010;28:583–8.PubMedCrossRef
22.
go back to reference Drobeniuc J, Meng J, Reuter G, Greene-Montfort T, Khudyakova N, Dimitrova Z, et al. Serologic assays specific to immunoglobulin M antibodies against hepatitis E virus: pangenotypic evaluation of performances. Clin Infect Dis. 2010;51:e24–7.PubMedCrossRef Drobeniuc J, Meng J, Reuter G, Greene-Montfort T, Khudyakova N, Dimitrova Z, et al. Serologic assays specific to immunoglobulin M antibodies against hepatitis E virus: pangenotypic evaluation of performances. Clin Infect Dis. 2010;51:e24–7.PubMedCrossRef
23.
go back to reference Khudyakov Y, Kamili S. Serological diagnostics of hepatitis E virus infection. Virus Res. 2011;161:84–92.PubMedCrossRef Khudyakov Y, Kamili S. Serological diagnostics of hepatitis E virus infection. Virus Res. 2011;161:84–92.PubMedCrossRef
24.
go back to reference Osterman A, Vizoso Pinto MG, Haase R, Nitschko H, Jäger S, Sander M, et al. Systematic screening for novel, serologically reactive hepatitis E virus epitopes. Virol J. 2012;9:28–36.PubMedCrossRef Osterman A, Vizoso Pinto MG, Haase R, Nitschko H, Jäger S, Sander M, et al. Systematic screening for novel, serologically reactive hepatitis E virus epitopes. Virol J. 2012;9:28–36.PubMedCrossRef
25.
go back to reference Kaufmann A, Kenfak-Foguena A, André C, Canellini G, Bürgisser P, Moradpour D et al. Hepatitis E virus seroprevalence among blood donors in southwest Switzerland. PLoS One. 2011;6:e21150.CrossRef Kaufmann A, Kenfak-Foguena A, André C, Canellini G, Bürgisser P, Moradpour D et al. Hepatitis E virus seroprevalence among blood donors in southwest Switzerland. PLoS One. 2011;6:e21150.CrossRef
26.
go back to reference Romanò L, Paladini S, Tagliacarne C, Canuti M, Bianchi S, Zanetti AR. Hepatitis E in Italy: a long-term prospective study. J Hepatol. 2011;54:34–40.PubMedCrossRef Romanò L, Paladini S, Tagliacarne C, Canuti M, Bianchi S, Zanetti AR. Hepatitis E in Italy: a long-term prospective study. J Hepatol. 2011;54:34–40.PubMedCrossRef
27.
go back to reference Zanetti AR, Dawson GJ. Hepatitis type E in Italy: a seroepidemiological survey. Study Group of Hepatitis E. J Med Virol. 1994;42:318–20.PubMedCrossRef Zanetti AR, Dawson GJ. Hepatitis type E in Italy: a seroepidemiological survey. Study Group of Hepatitis E. J Med Virol. 1994;42:318–20.PubMedCrossRef
28.
go back to reference Coppola RC, Masia G. Seroprevalence and epidemiological features of hepatitis E virus infection in Italy. In: Rizzetto M, Purcell RH, Jerin J, Verme G, editors. Viral hepatitis and liver disease. Torino: Minerva; 1997. p. 609–11. Coppola RC, Masia G. Seroprevalence and epidemiological features of hepatitis E virus infection in Italy. In: Rizzetto M, Purcell RH, Jerin J, Verme G, editors. Viral hepatitis and liver disease. Torino: Minerva; 1997. p. 609–11.
29.
go back to reference Gessoni G, Manoni F. Hepatitis E virus infection in north-east Italy: serological study in the open population and groups at risk. J Viral Hepat. 1996;3:197–202.PubMedCrossRef Gessoni G, Manoni F. Hepatitis E virus infection in north-east Italy: serological study in the open population and groups at risk. J Viral Hepat. 1996;3:197–202.PubMedCrossRef
30.
go back to reference Rapicetta M, Kondili LA, Pretolani S, Stroffolini T, Chionne P, Villano U, et al. Seroprevalence and anti-HEV persistence in the general population of the Republic of San Marino. J Med Virol. 1999;58:49–53.PubMedCrossRef Rapicetta M, Kondili LA, Pretolani S, Stroffolini T, Chionne P, Villano U, et al. Seroprevalence and anti-HEV persistence in the general population of the Republic of San Marino. J Med Virol. 1999;58:49–53.PubMedCrossRef
31.
go back to reference Fainboim H, González J, Fassio E, Martínez A, Otegui L, Eposto M, et al. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat. 1999;6:53–7.PubMedCrossRef Fainboim H, González J, Fassio E, Martínez A, Otegui L, Eposto M, et al. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat. 1999;6:53–7.PubMedCrossRef
32.
go back to reference Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361:1025–7.PubMedCrossRef Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361:1025–7.PubMedCrossRef
33.
go back to reference Kenfak-Foguena A, Schöni-Affolter F, Bürgisser P, Witteck A, Darling KEA, Kovari H, et al. Hepatitis E virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerg Infect Dis. 2011;17:1074–8.PubMedCrossRef Kenfak-Foguena A, Schöni-Affolter F, Bürgisser P, Witteck A, Darling KEA, Kovari H, et al. Hepatitis E virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerg Infect Dis. 2011;17:1074–8.PubMedCrossRef
34.
go back to reference Kondili LA, Chionne P, Porcaro A, Madonna E, Taffon S, Resuli B, et al. Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case–control study in Albania. Epidemiol Infect. 2006;134:95–101.PubMedCrossRef Kondili LA, Chionne P, Porcaro A, Madonna E, Taffon S, Resuli B, et al. Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case–control study in Albania. Epidemiol Infect. 2006;134:95–101.PubMedCrossRef
35.
go back to reference Sagnelli E, Stroffolini T, Almasio P, Mele A, Coppola N, Ferrigno L, et al. Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study. J Viral Hepat. 2006;13:67–71.PubMedCrossRef Sagnelli E, Stroffolini T, Almasio P, Mele A, Coppola N, Ferrigno L, et al. Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study. J Viral Hepat. 2006;13:67–71.PubMedCrossRef
36.
go back to reference Ansaldi F, Bruzzone B, Rota MC, Bella A, Ciofi degli Atti M, Durando P, et al. Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study. Eur J Epidemiol. 2008;23:45–53.PubMedCrossRef Ansaldi F, Bruzzone B, Rota MC, Bella A, Ciofi degli Atti M, Durando P, et al. Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study. Eur J Epidemiol. 2008;23:45–53.PubMedCrossRef
37.
go back to reference Gentile C, Alberini I, Manini I, Rossi S, Montomoli E, Pozzi T, et al. Hepatitis A seroprevalence in Tuscany, Italy. Euro Surveill. 2009;14. pii: 19146. Gentile C, Alberini I, Manini I, Rossi S, Montomoli E, Pozzi T, et al. Hepatitis A seroprevalence in Tuscany, Italy. Euro Surveill. 2009;14. pii: 19146.
38.
go back to reference Taffon S, Bidini G, Vichi F, Corti G, Genovese D, Kondili LA, et al. A unique HAV strain circulated in patients with acute HAV infection with different risk exposures in Tuscany, Italy. J Clin Virol. 2011;50:142–7.PubMedCrossRef Taffon S, Bidini G, Vichi F, Corti G, Genovese D, Kondili LA, et al. A unique HAV strain circulated in patients with acute HAV infection with different risk exposures in Tuscany, Italy. J Clin Virol. 2011;50:142–7.PubMedCrossRef
39.
go back to reference Spada E, Genovese D, Tosti ME, Mariano A, Cuccuini M, Proietti L, et al. An outbreak of hepatitis A virus infection with a high case–fatality rate among injecting drug users. J Hepatol. 2005;43:958–64.PubMedCrossRef Spada E, Genovese D, Tosti ME, Mariano A, Cuccuini M, Proietti L, et al. An outbreak of hepatitis A virus infection with a high case–fatality rate among injecting drug users. J Hepatol. 2005;43:958–64.PubMedCrossRef
Metadata
Title
Hepatitis E virus and hepatitis A virus exposures in an apparently healthy high-risk population in Italy
Authors
M. Rapicetta
R. Monarca
L. A. Kondili
P. Chionne
E. Madonna
G. Madeddu
A. Soddu
A. Candido
S. Carbonara
M. S. Mura
G. Starnini
S. Babudieri
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Infection / Issue 1/2013
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-012-0385-8

Other articles of this Issue 1/2013

Infection 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine